research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
Search
for
Sort by
Research
600-630 / 1000+ results 
research Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
An elderly Chinese man lost all his hair after taking a new heart medication.
research Lentiviral Arrays for Live-cell Dynamic Monitoring of Gene and Pathway Activity During Stem Cell Differentiation
The lentiviral array can monitor and predict gene activity during stem cell differentiation.
research Taurine‐based Active Pharmaceutical Ingredient Ionic Liquids Modulate the Perifollicular Microenvironment for Androgenic Alopecia Treatment
A new taurine-based liquid can help treat hair loss by improving hair follicle health and promoting regrowth.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Predictive value of the serum albumin change rate for therapeutic response to targeted therapy in patients with AIDS-related non-Hodgkin lymphoma
The albumin change rate helps predict treatment success in AIDS-related non-Hodgkin lymphoma.
research Relapsing Hepatitis A: An Asymptomatic Recurrence of Elevated Liver Chemistries
Relapsing hepatitis A can cause prolonged abnormal liver tests even without symptoms.
research Acorus calamus: a bio-reserve of medicinal values
*Acorus calamus* has many medicinal benefits but needs more safety research.
research ACTIVITY TEST OF ALOE VERA PEEL EXTRACT (ALOE VERA) GEL WITH RABBIT’S (Orycctolagus Cuniculus) COMBUSTIO (MINOR BURNS)
Aloe vera peel extract gel helps speed up the healing of minor burns in rabbits.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research Fludalanine: Nice Try But No Hallelujah
Fludalanine failed as an effective oral antibiotic despite efforts.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
research British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology
Acitretin is effective for severe skin conditions but has significant side effects and requires careful monitoring.
research Ectopic expression of FGF5s induces wool growth in Chinese merino sheep
Overexpression of FGF5s makes Chinese Merino sheep grow longer and heavier wool.
research Forensic skeletal and molecular anthropology face to face: Combining expertise for identification of human remains
Combining skeletal and molecular anthropology improves identifying human remains.
research Pure Leydig cell tumor of the ovary: a rare presentation of a rare entity in a pregnant patient
A rare benign ovarian tumor was found in a pregnant woman, but both mother and baby remained healthy.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research New food supplement cures alopecia
A new food supplement was highly effective in curing hair loss in young men.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
research EVALUATION OF THE EFFICACY OF PIX LIQUIDA FOR ALOPECIA AREATA: A CASE REPORT
Pix Liquida may help treat alopecia areata.
research Breaking the Hair-Loss Barrier: Pattern-Wise Efficacy of Verilich Serum
Verilich serum effectively and safely improves hair loss treatment.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research A Comparative Study of a New Food Supplement, ViviScal®, with Fish Extract for the Treatment of Hereditary Androgenic Alopecia in Young Males
ViviScal®, a food supplement, was found to be highly effective in treating hereditary hair loss in young males, while fish extract showed no impact.
research Role of the Autoimmune Regulator (AIRE) gene in alopecia areata: Strong association of a potentially functional AIRE polymorphism with alopecia universalis
A specific gene change is linked to severe hair loss.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Baricitinib works better in adolescents than adults for treating severe alopecia areata.